🇺🇸 FDA
Patent

US 12285473

Cancer vaccines targeting MUC16 and uses thereof

granted A61KA61K2039/53A61K2039/54

Quick answer

US patent 12285473 (Cancer vaccines targeting MUC16 and uses thereof) held by Inovio Pharmaceuticals, Inc. expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Inovio Pharmaceuticals, Inc.
Grant date
Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2039/53, A61K2039/54, A61K2039/572, A61K39/00117